Brief: Spero Therapeutics Announces Third Quarter 2022 Operating Results
14/11/2022 21:35
Nov 14 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS ANNOUNCES THIRD QUARTER 2022 OPERATING
RESULTS AND PROVIDES BUSINESS UPDATE
* SPERO THERAPEUTICS INC- REPORTED A NET LOSS FOR Q3 ENDED
SEPTEMBER 30, 2022, OF $11.7 MILLION OR $.33 PER COMMON SHARE
* SPERO THERAPEUTICS INC- AS OF SEPTEMBER 30, 2022, SPERO
HAD
CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $50.4
MILLION
Source text for Eikon: ID:nGNX41Q4VL
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)